CARB-X awards PHIOGEN $1.1 million for PHI-BI-01

CARB-X awarded PHIOGEN $1.1 million to evaluate PHI-BI-01, a phage-based candidate designed to treat and prevent ExPEC bloodstream infections. The project aims to pair immediate treatment with longer-term immune protection.